HECEIVED CENTRAL FAX CENTER

JAN 0 8 2008 CASE 4-32702A

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Cindy Klepacky

Linky Klepacky

1/8/08 Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1634

KUDARAVALLI ET AL.

Examiner: Pohnert, Steven C

APPLICATION NO: 10/529,613

FILED: MARCH 30, 2005

FOR: METHODS TO TREAT CHOLESTEROL ELEVATIONS DURING

IMMUNOSUPPRESSANT THERAPY

MS: Petition

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

PETITION TO REVIVE UNDER 37 CFR 1.137(b)

Sir:

Applicants respectfully request that the above-identified application be revived under the provisions of 37 CFR 1.137(b).

This application became abandoned for Applicant's failure to timely file a proper reply to the Office Action mailed on May 7, 2007.

In response to the Notice of Abandonment, Applicant's enclose a copy of

In accordance with 37 CFR 1.137(b)(2), the Commissioner is hereby authorized to charge the fee of \$1,500 required by 37 CFR 1.17(m) to Deposit Account No. 19-0134 in the name of Novartis. A duplicate copy of this Petition is also enclosed.

Novartis

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 77%-9308

Date:

Respectfully submitted,

Leslie Fischer

Attorney for Applicants

Reg. No. 58,393

01/09/2008, SSESHET 00000014 190134 10529613

01 (FG:1453 1540.00 DA

PTC/SB/64 (01-05)
Approved for use through 01/31/2008.0MB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no porsone are required to respond to a collection of information unloss it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT Docket Number (Optional) ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b) 4-32702 First named inventor; Sridhar Kudaravalli HEULIVEU CENTRAL FAX CENTER Application No.: 10/529613 Art Unit: 1634 JAN 0 8 2008 Filed: June 8, 2005 Examiner: Pohnert, Steven C. Title: METHODS TO PREDICT CHOLESTEROL ELEVATIONS DURING IMMUNOSUPPRESSANT THERAPY Attention: Office of Petitions Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 FAX (571) 273-8300 NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (571) 272-3282. The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained. APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION NOTE: A grantable petition requires the following items: (1) Petition fee, (2) Reply and/or issue fee: (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and (4) Statement that the entire delay was unintentional. 1.Petition fee Small entity-fee \$ _____ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27, ✓ Other than small entity – fee \$ 1540.00 (37 CFR 1.17(m)) 2. Reply and/or fee A. The reply and/or fee to the above-noted Office action in the form of Response to Restriction Requirement (identify type of reply): has been filed previously on ___ is enclosed herewith B. The issue fee and publication fee (if applicable) of \$ ____ has been paid previously on ___ is enclosed herewith. [Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden. Should be sent to the Chief Information Officer. U.S. Patent and Tradomark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

01/09/2008 SSESHE1 00000014 10529613

01 FC:1453 1540.00 DA

PTQ/5B/64 (01-08) Approved for use through 01/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no porsons are required to respond to a collection of information unless it displays a valid OMB control number. 3. Terminal disclaimer with disclaimer fee Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required. A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63), 4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional, [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D))] WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. Signature Date Leslie Fischer 58,393 Typed or printed name Registration Number, if applicable Novartis, One Health Plaza, East Hanover, NJ 07936-1080 862 778-9308 Address Telephone Number Address Enclosures: Fee Payment Reply Terminal Disclaimer Form Additional sheets containing statements establishing unintentional delay Other: Petition to expunde Information from an application CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)] I hereby certify that this correspondence is being: Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at/(571) 273-8300.

[Page 2 of 2]

Cindy Klepacky
Typed or printed name of person signing certificate